NCT04570839: COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PVRL2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: All breast cancer patients are eligible for the dose escalation phase of the study; Breast cancer patients with tumors that highly express PVRL2 are also eligible for the expansion phase
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients eligible for the expansion phase; Those with tumors expressing PVRL2 must not have had prior therapy with any inhibitor of PVRIG (e.g. COM701) or anti-TIGIT antibody

Comments are closed.

Up ↑